ADVANCED NON-SMALL CELL LUNG CANCER
Clinical trials for ADVANCED NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new ADVANCED NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for ADVANCED NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo tested for Tough-to-Treat lung cancer
Disease control OngoingThis early-stage study is testing the safety and side effects of combining an approved lung cancer drug (osimertinib/AZD9291) with one of two other experimental drugs (AZD6094 or selumetinib). It involves about 344 adults with advanced non-small cell lung cancer that has a specif…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New hope for lung cancer patients: testing powerful Immune-Based drug combos
Disease control OngoingThis study is testing several different combinations of immunotherapy drugs for people with advanced non-small cell lung cancer that has spread. The main goals are to see if these combinations can shrink tumors and to check how safe they are for patients. It will involve about 40…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New lung cancer drug challenges standard treatment in major trial
Disease control OngoingThis large Phase 3 trial compares a new drug called AK112 against the established treatment pembrolizumab for people with advanced non-small cell lung cancer. It aims to see if AK112 can better control the cancer and help patients live longer without their disease getting worse. …
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New targeted drug tested for Tough-to-Treat lung cancer
Disease control OngoingThis study is testing an experimental drug called DS-1062a for people with advanced non-small cell lung cancer that has spread and stopped responding to standard treatments. About 100 participants will receive the drug by IV every three weeks to see if it shrinks their tumors and…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New pill targets key drivers of advanced lung cancer in groundbreaking trial
Disease control OngoingThis early-stage study is testing a new oral medication called BAY 2927088 for people with advanced non-small cell lung cancer that has specific genetic changes (EGFR or HER2 mutations). The main goals are to find a safe and tolerable dose, understand how the drug moves through t…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Bayer • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New drug combo trial offers hope for advanced lung cancer patients
Disease control OngoingThis study is testing the safety and effectiveness of two immunotherapy drugs, AK112 and AK104, given with or without standard chemotherapy, for people with advanced non-small cell lung cancer. It aims to see if this combination can better control the cancer and help patients liv…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New hope for tough cancers: trial tests Next-Gen drug combo
Disease control OngoingThis study is testing a new drug called FF-10832, both by itself and combined with an existing immunotherapy (pembrolizumab), for people with advanced lung or bladder cancer. The main goals are to find a safe dose and see if the treatment can help control the cancer. It is for pa…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:29 UTC
-
New hope for tough-to-treat lung cancers as experimental drug enters human trials
Disease control OngoingThis early-stage study is testing an experimental drug called furmonertinib for people with advanced lung cancer that has specific genetic mutations. The trial aims to find the safest and most effective dose while checking if the drug can shrink tumors. It involves 160 patients w…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: ArriVent BioPharma, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New Two-Drug attack on advanced lung cancer enters major trial
Disease control OngoingThis large clinical trial is testing whether adding a new immunotherapy drug (fianlimab) to an existing one (cemiplimab) works better than the single drug alone for people with advanced non-small cell lung cancer. It involves about 850 patients whose cancer has not been treated b…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE2, PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Mar 16, 2026 15:23 UTC